Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.
Earnings for Oculis Holding AG (OCS)
Earnings in 2023 (TTM): $-88,695,000
According to Oculis Holding AG's latest financial reports the company's current earnings (TTM) are $-88,695,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Oculis Holding AG
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-88,695,000 | $-88,802,000 |
| 2022 | $-38,643,000 | $-38,698,000 |
| 2021 | $-18,524,000 | $-18,552,000 |
| 2020 | $-14,790,000 | $-14,873,000 |